CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Tau Therapeutics LLC announced today that its academic collaborators will present three posters at the American Association of Cancer Research’s 103rd annual meeting in Chicago, Illinois, March 31 – April 4, 2012. The posters will highlight the company’s non-toxic, selective T-type calcium channel inhibitors for the treatment of brain and breast cancers. The company’s approach, called Interlaced Therapy™, capitalizes on the central role of calcium influx through T-type calcium channels during cancer cell growth. In pre-clinical studies, T-type calcium channel blockade with Tau’s drugs arrests tumor cells at their most vulnerable metabolic point in the cell cycle, uniquely amplifying the effects of conventional therapies and overcoming drug resistance.
